Stock CDXC CHROMADEX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ChromaDex Corporation

Equities

CDXC

US1710774076

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.56 USD +3.49% Intraday chart for ChromaDex Corporation +20.68% +148.95%
Apr. 23 Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market CI
Apr. 09 Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
AQ
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
AQ
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BU
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
BU
ChromaDex Announces Tru Niagen is Now Third-Party Verified through the Alkemist Assured Transparency Program
AQ
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
BU
ChromaDex : March 2024 Investor Presentation
PU
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
BU
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
BU
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024
AQ
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
BU
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
BU
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen
AQ
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
BU
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
BU
ChromaDex - Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia Patients
AQ
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
BU
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
BU
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CDXC Stock
  4. News ChromaDex Corporation
  5. Press Releases